Q5112 Trastuzumab-dttb - CanMED: HCPCS

Return Home

Home

SEER Data & Software

Observational Research in Oncology Toolbox

Medication Information

CanMED: HCPCS

Generic Name:

Trastuzumab-dttb

Brand Name:

Ontruzant

Strength:

10mg

HCPCS:

Q5112

SEER*Rx Category:

Immunotherapy

Major Drug Class:

Monoclonal Antibody

Minor Drug Class:

HER2

Oral (Y/N):

No

FDA Approval Year:

2021

FDA Discontinuation Year:

CMS Effective Date:

July 1, 2019

CMS Discontinuation Date:

Status:

In Use